We are live on ! Find out more
CRXT

Clarus Therapeutics Holdings, Inc. Common Stock
CRXT

Delisted

CRXT was delisted on the 30th of August, 2022.

Back to rankings

2 hedge funds and large institutions have $5K invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less funds holding

Funds holding: 25 → 2 (-23)

100% less capital invested

Capital invested by funds: $1.82M → $5K (-$1.82M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 23

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-23
Holders Change %
-92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCL
Bracebridge Capital LLC
Massachusetts
-$761K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$397K
3
BlackRock
BlackRock
New York
-$124K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$115K
5
VF
Virtu Financial
New York
-$72K

CRXT Hedge Fund Activity: Q3 2022 in Review

2 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q3 2022, worth a combined $5K — down 100% from $1.82M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of CRXT and 0 opened new positions — a net loss of 23 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Bracebridge Capital LLC, exiting entirely with an estimated $761K sold.

  • 2 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q3 2022, down from 25 in Q2 2022.
  • Funds reported $5K of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q3 2022 and 23 closed out, a net change of -23 holders.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q3 2022 was Bracebridge Capital LLC, an estimated $761K sold.

Based on aggregated 13F filings for Q3 2022.